Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 23 April, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 532660 | NSE: VIVIMEDLAB

Fundamental Analysis of Vivimed Labs Ltd

Basic Stock Data

Last Updated: April 11, 2024, 7:06 am

Market Cap 41.0 Cr.
Current Price 4.95
High / Low6.97/4.85
Stock P/E
Book Value 21.3
Dividend Yield0.00 %
ROCE51.5 %
ROE163 %
Face Value 2.00

Data Source: screener.in

Competitors of Vivimed Labs Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Chandra Bhagat Pharma Ltd 86.6 Cr. 115160/80.074.1 37.30.00 %7.13 %3.36 % 10.0
Brooks Laboratories Ltd 268 Cr. 102186/56.5 30.10.00 %27.7 %23.4 % 10.0
Ortin Laboratories Ltd 15.9 Cr. 19.530.4/16.2 12.00.00 %1.80 %0.64 % 10.0
Kopran Ltd 1,287 Cr. 267292/14031.9 91.61.12 %8.30 %6.29 % 10.0
Sun Pharmaceuticals Industries Ltd 3,56,333 Cr. 1,4851,639/92238.1 2490.77 %16.4 %16.6 % 1.00
Industry Average71,598.10 Cr397.7028.8284.000.38%12.27%10.06%8.20

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales278396554576150445637353441
Expenses3005554656462595461201364040
Operating Profit-22-1611-10-7-1-9-9-5-164-0-61
OPM %-8%-42%17%-19%-13%-2%-17%-21%-9%-444%-1%-18%3%
Other Income4210-010001020
Interest16910912109999111213
Depreciation174544544496555
Profit before tax-50-28-2-23-24-16-22-22-18-268-16-20-17
Tax %1%2%0%0%0%-18%0%0%0%1%0%0%3%
Net Profit-50-27-2-23-24-18-22-22-18-266-16-20-16
EPS in Rs-5.98-3.31-0.28-2.81-2.86-2.21-2.68-2.66-2.21-32.08-1.88-2.45-1.94

Last Updated: April 10, 2024, 4:47 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: April 5, 2024, 2:25 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales6681,1091,3511,3801,3461,4621,1861,3151,059861237187147
Expenses5389161,1391,1561,1111,0579711,1351,049830245374317
Operating Profit1301932122242344042151801032-8-187-169
OPM %20%17%16%16%17%28%18%14%1%4%-3%-100%-115%
Other Income312861181023810113
Interest28486786846882706156403644
Depreciation2759666661585667675618108110
Profit before tax789887781002868666-109-70-65-331-321
Tax %19%15%24%7%16%25%11%13%0%-3%-4%1%
Net Profit63846672842147657-109-72-68-329-318
EPS in Rs9.0610.418.208.9010.3326.419.446.95-13.16-8.67-8.16-39.62-38.35
Dividend Payout %7%6%7%0%0%2%4%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)33.33%-21.43%9.09%16.67%154.76%-64.49%-25.00%-291.23%33.94%5.56%-383.82%
Change in YoY Net Profit Growth (%)0.00%-54.76%30.52%7.58%138.10%-219.25%39.49%-266.23%325.17%-28.39%-389.38%

Growth

Compounded Sales Growth
10 Years:-16%
5 Years:-31%
3 Years:-44%
TTM:-30%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-293%
Stock Price CAGR
10 Years:-20%
5 Years:-28%
3 Years:-37%
1 Year:-21%
Return on Equity
10 Years:0%
5 Years:-22%
3 Years:-44%
Last Year:-163%

Last Updated: April 11, 2024, 7:06 am

Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital14161616161617171717171717
Reserves32842747847950571888560249341534823160
Preference Capital131646464640325325325000
Borrowings5646658941,0129511,011824955943326359379320
Other Liabilities393468470391583317668756758532543651714
Total Liabilities1,2991,5771,8581,8982,0552,0622,3942,3292,2101,2891,2661,0691,210
Fixed Assets5957098088138148791,0359651,045502520436522
CWIP82738909476651228960402121
Investments1003333386199199199192
Other Assets6958401,0119921,1441,1041,2901,239990529507414476
Total Assets1,2991,5771,8581,8982,0552,0622,3942,3292,2101,2891,2661,0691,210

Reserves and Borrowings Chart

Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 4590-1181401545821422805672835
Cash from Investing Activity -424-170-291-107-190-68-164-89-196404-16-5
Cash from Financing Activity 40467419-424135186-33872-1,015-10-34
Net Cash Flow25-1211-842544-5-44-441-3

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow-1.00129.00148.00160.00170.00404.00-110.00-145.00-315.0032.00-8.00-187.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days1211019487885085998646134150
Inventory Days268247249244294329411397396263573216
Days Payable170118106107981221542071793510093
Cash Conversion Cycle220230237224285258342288303274607273
Working Capital Days208161159146169151239161216190653588
ROCE %14%13%12%11%12%22%9%7%-3%-1%-3%-52%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters28.57%28.57%28.57%28.57%21.98%20.96%20.96%20.96%20.94%20.94%20.94%20.94%
FIIs3.10%2.66%1.85%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%
Government0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%
Public68.21%68.65%69.47%69.67%76.27%77.29%77.28%77.29%77.30%77.30%77.29%77.30%
No. of Shareholders37,98951,96350,92852,07453,11053,37652,39851,02650,68349,50349,03849,027

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)-39.62-8.16-8.67-13.166.95
Diluted EPS (Rs.)-39.62-7.92-8.42-12.776.67
Cash EPS (Rs.)-26.55-5.95-1.98-5.0915.04
Book Value[Excl.RevalReserv]/Share (Rs.)0.1739.3547.4756.8570.35
Book Value[Incl.RevalReserv]/Share (Rs.)4.7543.9352.0561.4374.96
Revenue From Operations / Share (Rs.)22.5728.62103.90127.70159.37
PBDIT / Share (Rs.)-22.47-0.814.771.9724.25
PBIT / Share (Rs.)-35.55-3.02-1.93-6.1016.15
PBT / Share (Rs.)-39.88-7.82-8.43-13.208.00
Net Profit / Share (Rs.)-39.62-8.16-8.67-13.166.95
NP After MI And SOA / Share (Rs.)-39.62-8.16-8.67-13.166.95
PBDIT Margin (%)-99.59-2.864.581.5415.21
PBIT Margin (%)-157.53-10.56-1.85-4.7710.13
PBT Margin (%)-176.72-27.32-8.10-10.335.02
Net Profit Margin (%)-175.59-28.50-8.34-10.304.36
NP After MI And SOA Margin (%)-175.59-28.50-8.34-10.304.36
Return on Networth / Equity (%)-23087.35-20.73-18.26-23.149.88
Return on Capital Employeed (%)-52.25-2.80-1.68-3.519.25
Return On Assets (%)-33.24-5.34-5.57-4.932.46
Long Term Debt / Equity (X)43.790.180.140.990.73
Total Debt / Equity (X)266.031.100.641.891.30
Asset Turnover Ratio (%)0.160.180.120.160.14
Current Ratio (X)0.781.361.551.271.38
Quick Ratio (X)0.590.710.800.610.75
Inventory Turnover Ratio (X)1.170.570.240.370.31
Dividend Payout Ratio (NP) (%)0.000.000.000.00574.49
Dividend Payout Ratio (CP) (%)0.000.000.000.00265.44
Earning Retention Ratio (%)0.000.000.000.00-474.49
Cash Earning Retention Ratio (%)0.000.000.000.00-165.44
Interest Coverage Ratio (X)-5.19-0.170.730.272.97
Interest Coverage Ratio (Post Tax) (X)-8.15-0.70-0.33-0.851.85
Enterprise Value (Cr.)430.11471.51378.03898.62854.91
EV / Net Operating Revenue (X)2.301.990.430.840.65
EV / EBITDA (X)-2.31-69.449.5754.914.27
MarketCap / Net Operating Revenue (X)0.290.500.150.050.14
Retention Ratios (%)0.000.000.000.00-474.49
Price / BV (X)38.870.360.330.120.33
Price / Net Operating Revenue (X)0.290.500.150.050.14
EarningsYield-5.94-0.56-0.54-1.810.29

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 531.20

The stock is undervalued by 10,631.33% compared to the current price ₹4.95

Calculation basis:

  • Fair value = (P/E Ratio * (Return on Equity / 100) * Book Value) * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (450.85 cr) compared to borrowings (104.77 cr), indicating strong financial stability.
  1. The stock has a low average ROCE of 3.42%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 253.42, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 295.08, which may not be favorable.
  4. The company has not shown consistent growth in sales (162.15) and profit (-1.31).

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vivimed Labs Ltd:
    1. Net Profit Margin: -175.59%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -52.25% (Industry Average ROCE: 20.69%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -23087.35% (Industry Average ROE: 19.85%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -8.15
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.59
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✓ Stock P/E of N/A (Industry average Stock P/E: 12.98)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 266.03
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating: ★︎☆☆☆☆

About the Company

Vivimed Labs Ltd. is a Public Limited Listed company incorporated on 22/09/1988 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L02411KA1988PLC009465 and registration number is 009465. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 218.37 Cr. and Equity Capital is Rs. 16.58 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No. 78/A, Kolhar Industrial Area, Bidar Karnataka 585403yugandhar.kopparthi@vivimedlabs.com
http://www.vivimedlabs.com
Management
NamePosition Held
Mr. Sandeep VaralwarWhole Time Director
Dr. Jamalapuram HarigopalChairman & Ind.Director
Mr. Subhash VaralwarNon Executive Director
Mr. Santosh VaralwarManaging Director
Dr. Manohar Rao VaralwarWhole Time Director
Ms. Aparna BidarkarIndependent Director

Vivimed Labs Ltd. Share Price Update

Share PriceValue
Today₹4.90
Previous Day₹4.90

FAQ

What is the latest fair value of Vivimed Labs Ltd?

The latest fair value of Vivimed Labs Ltd is 531.20.

What is the Market Cap of Vivimed Labs Ltd?

The Market Cap of Vivimed Labs Ltd is 41.0 Cr..

What is the current Stock Price of Vivimed Labs Ltd as on 14 April 2024?

The current stock price of Vivimed Labs Ltd as on 14 April 2024 is 4.95.

What is the High / Low of Vivimed Labs Ltd stocks in FY 2024?

In FY 2024, the High / Low of Vivimed Labs Ltd stocks is ₹6.97/4.85.

What is the Stock P/E of Vivimed Labs Ltd?

The Stock P/E of Vivimed Labs Ltd is .

What is the Book Value of Vivimed Labs Ltd?

The Book Value of Vivimed Labs Ltd is 21.3.

What is the Dividend Yield of Vivimed Labs Ltd?

The Dividend Yield of Vivimed Labs Ltd is 0.00 %.

What is the ROCE of Vivimed Labs Ltd?

The ROCE of Vivimed Labs Ltd is 51.5 %.

What is the ROE of Vivimed Labs Ltd?

The ROE of Vivimed Labs Ltd is 163 %.

What is the Face Value of Vivimed Labs Ltd?

The Face Value of Vivimed Labs Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vivimed Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE